Study S002410

A Phase I Pharmacokinetic Study of VCT220 in Subjects With Varying Degrees of Hepatic Impairment and Normal Hepatic Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06938529
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2025-04-18
Primary completion: 2025-07-15
Lead sponsor: Vincentage Pharma Co., Ltd
Conditions: Obesity, Overweight
Interventions: DRUG:VCT220; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Peak Plasma Concentration (Cmax) of VCT220 [Predose up to 72 hours postdose (D1 to D4)]
Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of VCT220 [Predose up to 72 hours postdose (D1 to D4)]
Area Under the Serum Concentration Curve From Time 0 to Infinity(AUC0-inf) of VCT220 [Predose up to 72 hours postdose (D1 to D4)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.